Abstract No. 556 Cost-effectiveness of radioembolization with Y-90 glass microspheres versus transarterial chemotherapies in the treatment of intermediate stage hepatocellular carcinoma: a U.S. hospital perspective

Abstract

Transarterial radioembolization with Y-90 glass microspheres (“Y-90”) is a safe and effective alternative to transarterial chemoembolization (TACE) in patients with intermediate stage hepatocellular carcinoma (HCC). A previous economic evaluation from the UK National Health Service perspective found Y-90 to be cost-effective compared with TACE and transarterial bland embolization (TAE) in a population of unresectable HCC patients. This economic evaluation assessed the cost-effectiveness of Y-90 across the same patient population in the U.S.